Vaccines and COPD: The Facts 


  • Reading time

    5 min read

  • Rating

  • Your expert

    Expert Placeholder
    GSK
  • Key subject matter / tags

Key Takeaways

Placeholder
  • Current guidelines recommend influenza and pneumococcal vaccination for COPD patients1,2
  • Influenza and pneumonia vaccinations are known to decrease the incidence of lower respiratory tract infections1
  • Use key messages to advise your patient on the risks and benefits of vaccination

Consulting the guidelines

Pneumonia and influenza cause an increase in morbidity and mortality in COPD patients3,4 As such:

  • NICE recommend that you offer your COPD patients a pneumococcal vaccination and an annual flu vaccination, to reduce the risk of flu and pneumonia.2
  • GOLD recommend offering an influenza vaccine to all COPD patients and provides detailed advice on pneumoccocal vaccination.1

What does the data say?

Studies indicate that influenza and pneumococcal vaccination can benefit COPD patients.3,5

  • Pneumococcal vaccination can reduce patients’ risk of experiencing community-acquired pneumonia vs placebo. Anticipated absolute risk of 94 cases per 1000 patients with vaccine and 143 cases per 1000 patients with placebo control. Odds ratio = 0.62 (95% CI: 0.43 to 0.89). However, no difference was reported for the risk of developing pneumococcal pneumonia. Anticipated absolute risk of 3 cases per 1000 patients with vaccine and 11 cases per 1000 patients with placebo control. Peto odds ratio = 0.26 (95% CI: 0.05 to 1.31). Also, no differences were reported for mortality due to cardiorespiratory diseases, all-cause mortality or hospitalisations, or hospitalisations due to cardiorespiratory causes.3
  • Patients receiving pneumococcal vaccination are less likely to experience a COPD exacerbation vs control. Anticipated absolute risk of 482 per 1000 with vaccine and 608 per 1000 with placebo control. Odds ratio = 0.60 (95% CI: 0.39 to 0.93).3
  • One randomised controlled trial (RCT) indicated that patients who receive influenza vaccinations have a lower risk of influenza-related acute respiratory illness compared with patients who receive placebo. 4 of 62 vaccinated patients and 17 of 63 unvaccinated patients experienced influenza-related acute respiratory illness, a vaccine effectiveness of 76%.5

Advising your patient

When offering your patient access to vaccination it is important to consider that they may be hesitant.

Try sharing key messages with your COPD patient:

  • They are at greater risk of pneumonia compared with people without COPD3
  • Pneumococcal vaccination can reduce the risk of developing community-acquired pneumonia3
  • Contracting flu may affect the progression of their COPD and frequency of exacerbations4
  • There are some mild side effects associated with the flu and pneumococcal vaccines including mild fever, aching muscles, and soreness and redness at the site of injection, but serious side effects are very rare6,7
Remember that any information provided should be simple and easy to understand.

Summary

Influenza and community-acquired pneumonia can present more serious problems in patients with COPD, but you can help prevent occurrence by encouraging vaccination.

Guidelines recommend influenza and pneumococcal vaccination and these recommendations are supported by study data. If your patient is hesitant, you can share key messages to help advise them on the risks and benefits.


References

PM-GB-CPU-WCNT-190006 - May 2019

Rate this article

By sharing your feedback, you are helping us to provide you with more content that you find useful and relevant. Win-Win!

Enjoyed this article?

Stay up to date with relevant respiratory content and join the thousands of UK healthcare professionals subscribed to our updates

  • Reading time

    5 min read

  • Rating

  • Your expert

    Expert Placeholder
    GSK
  • Key subject matter / tags

Sign up today!

Join the thousands of UK healthcare professionals subscribed to our updates.

Emails may contain promotional information from GSK and its group You can change your mind at anytime and unsubscribe from our mailing list. Please click here to see our privacy notice.

PM-GB-CAU-WCNT-190006
March 2019